Answers are grounded in this paper and cite their sources.
Chronic inducible urticaria (CIndU) is a common inflammatory skin disorder. Currently there are no recommended guidelines on using anti-IgE antibody, omalizumab in CIndU. We describe five cases [three cases of IgE mediated immunological contact urticaria, one case of delayed pressure urticaria (DPU) and one case of Symptomatic Dermographism (SD)]. Four of these cases achieved complete symptom control (rapid responder) (UAS 7 improvement: Case 1-29 to 4, Case 2-30 to 5, Case 3-32 to 4 and Case 5-30 to 5) while one case of DPU was a slow responder (Case 4-UAS 7 improved from 28 to 11). Three cases of IgE mediated immunological contact urticaria had higher baseline total IgE with positive skin prick test and specific IgE to food and aero-allergens, signifies the successful response to omalizumab. Once disease control is achieved, the strategy for duration of the omalizumab therapy has not been determined. We hypothesize that omalizumab given at monthly doses, is a safe, effective and well tolerated therapeutic option in antihistamine-refractory CIndU.
No takes yet. Share an insight, caveat, or question.
Kathuria Pc (2021) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: